Phathom Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Phathom Pharmaceuticals generated cash of -$137,580,000, which is more than the previous year. Cash used in financing activities reached the amount of $367,580,000 last year. Net change in cash is therefore $228,366,000.
Cash Flow
| 2018 | -1.02M | 0 | 1.90M |
|---|---|---|---|
| 2019 | -36.51M | -25.25M | 304.64M |
| 2020 | -69.68M | -1.04M | 114.45M |
| 2021 | -148.61M | -328K | 44.70M |
| 2022 | -146.53M | -1.04M | 120.04M |
| 2023 | -137.58M | -1.63M | 367.58M |
PHAT Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 155.89M | 183.41M | 287.49M | 243.76M | 879K | 0 |
Operating activities | ||||||
Net income | -201.59M | -197.72M | -143.88M | -129.06M | -255.13M | -1.28M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 575K | 620K | 521K | 323K | 8K | 0 |
Stock-based compensation expense | 45.02M | 24.13M | 16.81M | 5.84M | 406K | 0 |
| Deferred income tax benefit | 45.02M | 24.13M | 16.81M | 5.84M | 406K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -1.63M | 0 | 0 | 0 | 0 | 0 |
Inventories | -9.44M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 6.41M | 8.67M | -9.79M | 24.00M | 2.26M | 225K |
Cash generated by operating activities | -137.58M | -146.53M | -148.61M | -69.68M | -36.51M | -1.02M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.63M | -1.04M | -328K | -1.04M | -25.25M | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -1.63M | -1.04M | -328K | -1.04M | -25.25M | 0 |
Financing activities | ||||||
Common Stock Issued | 155.46M | 24.59M | 1.29M | 88.83M | 191.47M | 2K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 39.31M | 0 | -54.12M | -25M | 24.85M | 0 |
Cash used in financing activities | 367.58M | 120.04M | 44.70M | 114.45M | 304.64M | 1.90M |
Net Change In Cash | 228.36M | -27.52M | -104.23M | 43.73M | 242.88M | 879K |
Cash at end of period | 384.25M | 155.89M | 183.25M | 287.49M | 243.76M | 879K |
| Data source | Data source | Data source | Data source | Data source |